Akeso Biopharma (9926. HK) ("Akeso", the "Company" ) announced that it has successfully raised approximately $250 million USD through a share placement. This offering has earned notable recognition ...
Our rating is supported by the intangible assets moat source stemming from strong brand equity across its diverse portfolio. This competitive advantage has translated into impressive financial success ...